Ignite Creation Date:
2024-05-05 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00444223
Status:
TERMINATED
Last Update Posted:
2020-08-05
First Post:
2007-03-05
Brief Title:
Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants
Sponsor:
Jonsson Comprehensive Cancer Center
Organization:
Jonsson Comprehensive Cancer Center
Study Overview
Official Title:
The Biodistribution of N-4-3-F-18 FluoroethylphenylAmino-6-quinazolinyl-Acrylamide F-F18FEQA in Patients With Advanced Non-Small-Cell Lung Cancer NSCLC and in Healthy Subjects A Pilot Study
Status:
TERMINATED
Status Verified Date:
2016-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
poor recruitment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Fluorine F 18 FEQA may be an effective radioactive drug to use with positron emission tomography PET scans
PURPOSE This clinical trial is studying the use of fluorine F 18 FEQA in patients with stage III or stage IV non-small cell lung cancer and in healthy participants
PURPOSE This clinical trial is studying the use of fluorine F 18 FEQA in patients with stage III or stage IV non-small cell lung cancer and in healthy participants
Detailed Description:
OBJECTIVES
Determine the biodistribution of fluorine F 18 FEQA in patients with stage III or IV non-small cell lung cancer NSCLC and in healthy participants
Determine whether fluorine F 18 FEQA can be used as an imaging agent with positron emission tomography in patients with stage III or IV NSCLC
OUTLINE This is a pilot study
Patients and healthy participants receive fluorine F 18 FEQA IV and then undergo whole-body dynamic scans comprising positron emission tomography
Blood is collected during and after imaging to measure radioactivity
PROJECTED ACCRUAL A total of 30 patients will be accrued for this study
Determine the biodistribution of fluorine F 18 FEQA in patients with stage III or IV non-small cell lung cancer NSCLC and in healthy participants
Determine whether fluorine F 18 FEQA can be used as an imaging agent with positron emission tomography in patients with stage III or IV NSCLC
OUTLINE This is a pilot study
Patients and healthy participants receive fluorine F 18 FEQA IV and then undergo whole-body dynamic scans comprising positron emission tomography
Blood is collected during and after imaging to measure radioactivity
PROJECTED ACCRUAL A total of 30 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| UCLA-0304039-01 | None | None | None |